Literature DB >> 32239674

Acute kidney injury after ruxolitinib: Common complication, uncommon cause.

Samuel Strohbehn1, Harish Seethapathy1, Nifasha Rusibamayila1, Ian Strohbehn2, Meghan Lee2, Gabriela Hobbs3, Alla Keyzner4, Kenar D Jhaveri5, Meghan E Sise1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32239674      PMCID： PMC8018792          DOI： 10.1002/ajh.25804

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  4 in total

1.  Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.

Authors:  Francisco Cervantes; Alessandro M Vannucchi; Jean-Jacques Kiladjian; Haifa Kathrin Al-Ali; Andres Sirulnik; Viktoriya Stalbovskaya; Mari McQuitty; Deborah S Hunter; Richard S Levy; Francesco Passamonti; Tiziano Barbui; Giovanni Barosi; Claire N Harrison; Laurent Knoops; Heinz Gisslinger
Journal:  Blood       Date:  2013-10-30       Impact factor: 22.113

2.  Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease.

Authors:  Hanna Jean Khoury; Amelia A Langston; Vamsi K Kota; Jennifer A Wilkinson; Iskra Pusic; Anand Jillella; Stephanie Bauer; Audrey S Kim; Danielle Roberts; Zaid Al-Kadhimi; Imre Bodo; Elliott Winton; Martha Arellano; John F DiPersio
Journal:  Bone Marrow Transplant       Date:  2018-01-24       Impact factor: 5.483

3.  Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

Authors:  Alessandro M Vannucchi; Jean Jacques Kiladjian; Martin Griesshammer; Tamas Masszi; Simon Durrant; Francesco Passamonti; Claire N Harrison; Fabrizio Pane; Pierre Zachee; Ruben Mesa; Shui He; Mark M Jones; William Garrett; Jingjin Li; Ulrich Pirron; Dany Habr; Srdan Verstovsek
Journal:  N Engl J Med       Date:  2015-01-29       Impact factor: 91.245

4.  Ruxolitinib therapy is associated with improved renal function in patients with primary myelofibrosis.

Authors:  Paolo Strati; Maen Abdelrahim; Umut Selamet; Valda D Page; Sherry A Pierce; Srdan Verstovsek; Ala Abudayyeh
Journal:  Ann Hematol       Date:  2019-05-15       Impact factor: 3.673
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.